Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole,
200 mg twice daily, for 60 days, prior to curative intent surgery.